Baxter International Inc. (NYSE:BAX) SVP Jeanne K. Mason sold 33,350 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $65.25, for a total value of $2,176,087.50. Following the completion of the transaction, the senior vice president now directly owns 124,609 shares of the company’s stock, valued at approximately $8,130,737.25. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Baxter International Inc. (NYSE:BAX) traded down $0.23 during mid-day trading on Wednesday, reaching $64.02. The company had a trading volume of 2,562,400 shares, compared to its average volume of 2,698,777. Baxter International Inc. has a 12-month low of $43.13 and a 12-month high of $66.18. The firm has a market cap of $35,005.45, a PE ratio of 26.55, a price-to-earnings-growth ratio of 2.15 and a beta of 0.69. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.80 and a quick ratio of 2.22.
Baxter International (NYSE:BAX) last released its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $0.64 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.59 by $0.05. Baxter International had a return on equity of 15.00% and a net margin of 9.88%. The firm had revenue of $2.71 billion during the quarter, compared to analysts’ expectations of $2.66 billion. During the same period last year, the firm posted $0.56 EPS. The business’s revenue was up 5.8% on a year-over-year basis. equities research analysts forecast that Baxter International Inc. will post 2.43 earnings per share for the current year.
Several equities analysts have commented on the company. Bank of America reaffirmed a “hold” rating on shares of Baxter International in a report on Wednesday, November 22nd. Royal Bank Of Canada reaffirmed a “hold” rating and issued a $66.00 price target on shares of Baxter International in a report on Wednesday, November 22nd. Stifel Nicolaus reissued a “hold” rating and issued a $65.00 target price on shares of Baxter International in a report on Thursday, October 26th. Barclays increased their target price on Baxter International from $70.00 to $73.00 and gave the stock an “overweight” rating in a report on Thursday, October 26th. Finally, Morgan Stanley increased their target price on Baxter International from $59.00 to $62.00 and gave the stock an “equal weight” rating in a report on Thursday, October 26th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $67.46.
A number of hedge funds have recently added to or reduced their stakes in BAX. Baker Ellis Asset Management LLC acquired a new stake in Baxter International during the 2nd quarter valued at $109,000. BP PLC increased its holdings in Baxter International by 118.8% during the 2nd quarter. BP PLC now owns 151,000 shares of the medical instruments supplier’s stock valued at $9,140,000 after purchasing an additional 82,000 shares in the last quarter. Cigna Investments Inc. New increased its holdings in Baxter International by 8.7% during the 2nd quarter. Cigna Investments Inc. New now owns 21,494 shares of the medical instruments supplier’s stock valued at $1,305,000 after purchasing an additional 1,723 shares in the last quarter. Canada Pension Plan Investment Board increased its holdings in Baxter International by 16.1% during the 2nd quarter. Canada Pension Plan Investment Board now owns 1,040,554 shares of the medical instruments supplier’s stock valued at $62,995,000 after purchasing an additional 144,400 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in Baxter International by 1.5% during the 2nd quarter. Rhumbline Advisers now owns 837,314 shares of the medical instruments supplier’s stock valued at $50,691,000 after purchasing an additional 12,633 shares in the last quarter. 83.59% of the stock is owned by hedge funds and other institutional investors.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.